Mitigating the Regulatory Constraints Imposed by Intellectual Property Rules...
Carlos Correa South Centre, February 2017 Research Paper #74 IP provisions in FTAs may have implications on a wide range of public policy areas. A vast academic literature has addressed the...
View ArticleOpen Letter to Ministers of Trade from Trans-Pacific Partnership Agreement...
Joint letter signed by 43 civil society organizations Dear Ministers: As organisations representing health professionals and health advocates from countries that are signatories to the Trans-Pacific...
View ArticleData Exclusivity Exceptions and Compulsory Licensing to Promote Generic...
Authors: Ellen F.M. ‘t Hoen, Pascale Boulet and Brook K. Baker Abstract: The challenge of providing access to high-priced patented medicines is a global problem affecting all countries. A decade and a...
View ArticleMSF challenges Gilead’s patent application for hepatitis C combination...
[MSF] The international medical humanitarian organisation, Médecins Sans Frontières (MSF) has filed a legal patent challenge in China against US pharmaceutical corporation Gilead’s patent application...
View ArticleMSF: Open Letter to European Commissioner on EU India Free Trade Agreement...
[Els Torreele] On behalf of Médecins Sans Frontières (MSF), an international medical humanitarian organisation that provides emergency medical assistance to populations in distress in more than 70...
View ArticleThe Drug Debate: Data Exclusivity is the New Way to Delay Generics
[Srividhya Ragavan] Abstract: The article discusses the protection regime for clinical trial data internationally and outlines the applicable protection regime. In doing so, this article outlines how...
View ArticleOpen Letter to Johnson & Johnson: Calling for Affordable Access to Critical...
[Medicins Sans Fronteirs] Dear Dr Stoffels: For the past decade, Médecins Sans Frontières (MSF) has been in dialogue with Johnson & Johnson (J&J) about the critically important TB drug...
View ArticleSouth Centre Statement to the Third High-Level Meeting on the Prevention and...
[Carlos Correa, South Centre]... More progress needs to be made to improve access to affordable, good-quality essential medicines and vaccines for all. In addition to increasing investment in access,...
View ArticleBiological Drugs – Challenges to Access
[Third World Network] In this paper Dr. Sengupta examines the landscape of biological medicines, and locates this analysis in the characteristics of biological drugs which set them apart from small...
View ArticleNew Database Documents the Power of TRIPS Flexibilities
[Ellen 't Hoen] Medicines Law & Policy has published an on-line database of instances of the use of TRIPS flexibilities in public health contexts, titled the TRIPS Flexibilities Database. The...
View ArticleMay 20: Webinar on the USMCA (NAFTA 2.0) and Access to Medicines
How will the recently-concluded United States-Mexico-Canada Agreement (USMCA) impact access to affordable medicines? The USMCA – the renegotiated North American Free Trade Agreement (also commonly...
View ArticleResearch Synthesis: Patentability Criteria
[Marcela Vieira and Suerie Moon] We would like to share with you a new research synthesis on patentability criteria in the pharmaceutical sector. It can be accessed at...
View ArticleA Public Health-Oriented Examination of Pharmaceutical Patent Claims: Sharing...
[Lucas van der Hoeven] How to examine pharmaceutical patent applications to ensure access to affordable generic medicines while rewarding genuine pharmaceutical inventions, in accordance with the World...
View ArticleThe COVID-19 Pandemic: R&D and Intellectual Property Management for Access to...
[Viviana Muñoz Tellez] The ongoing rapid spread of COVID-19 is challenging the capacity of governments and of the World Health Organization (WHO) to timely put in place a global coordinated response to...
View Article